Nachrichten zur Arctic Bioscience AS Aktie

Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as…

The Annual General Meeting of Arctic Bioscience AS was held Friday 26 April 2024 at 11:00 (CET). All the items…

Arctic Bioscience AS’ Annual General Meeting will be held Friday 26 April 2024 at 11:00 (CET), as a digital meeting. Shareholders…

Arctic Bioscience has today released its Annual Report 2023, including the Board of Directors report and financial statements. The report…

The Board of Directors of Arctic Bioscience AS has resolved to extend the share option agreements for the following members…

Highlights Q4 2023: · The HeROPA clinical trial fully recruited in January 2024 · Available liquidity end of…

With reference to the stock exchange announcement from 17. January 2024 which reported that the HeROPA phase IIb clinical trial…

Arctic Bioscience will publish a Q4 2023 operational update and preliminary full year 2023 financial results on Friday 1[st] of…

With reference to the stock exchange announcement from December 1[st] 2023 which reported more than 75% patients recruited to the…

With reference to the Q3 update from November 2[nd] 2023 which reported more than 50% recruited patients to the phase IIb clinical…

Highlights Q3 2023: · Good progress in patient recruitment for the phase IIb HeROPA clinical trial, more than 50%…

Arctic Bioscience will publish its financial results for the half year 2023 on Tuesday 29[th] of August, at 08:00 CET. The…

Through the companys primary bank, Arctic Bioscience has established a credit facility of NOK 30 million to support the nutra…

Reference is made to the stock exchange release published by Arctic Bioscience 21 April 2023 regarding the Annual General Meetings…

Highlights Q1 2023: · The phase IIb HeROPA clinical trial approved in all the five European countries where the…

Reference is made to the stock exchange release regarding approval of share capital increase, published 21st April 2023. Ronja Capital II…

Reference is made to the stock exchange release published by Arctic Bioscience earlier today 21 April 2023 regarding minutes from…

The Annual General Meeting of Arctic Bioscience AS was held Friday 21 April 2023 at 14:00 (CET). All the items…

Arctic Bioscience AS Annual General Meeting will be held Friday 21 April 2023 at 14:00 (CET), as a digital meeting. Shareholders…

Arctic Bioscience has today released its Annual Report 2022, including the Board of Directors report and financial statements. The report…

Arctic Bioscience will publish its annual report 2022 on Wednesday 29 March 2023, at 08:00 CET. On Thursday 30 March 2023,…

Reference is made to the stock exchange release published by Arctic Bioscience 7th March 2023 regarding Board approval of share…

The Board of Directors of Arctic Bioscience AS has resolved to extend the share option agreements for the following members…

Reference is being made to the stock exchange release from January 12[th], 2023, where Arctic Bioscience announced that the Clinical…

Reference is made to the stock exchange release published by Arctic Bioscience 27th February 2023 regarding exercise of share options…

Daniele Mancinelli, CTO in Arctic Bioscience, has exercised 50.000 share options at a strike price of NOK 9,845 per share. The…

Runhild Gammelsæter, Medical Director in Arctic Bioscience, has today bought 11,500 shares in Arctic Bioscience at an average price of…

Reference is made to stock exchange release from earlier today regarding acquisition of Arctic Algae AS. Attached is account for…

Arctic Bioscience, a biotech company developing and commercializing pharmaceutical and nutraceutical products, today announces the acquisition of Arctic Algae AS,…

Highlights Q4 2022: · Positive development for psoriasis drug candidate HRO350 according to plan, with approval of the Clinical…

Reference is being made to the stock exchange release from January 12[th] 2023 where Arctic Bioscience announced that the Clinical…

Reference is being made to the stock exchange release from October 10th 2022, where Arctic Bioscience announced that Clinical Trial…

Highlights Q3 2022: · HRO350 development on track with CTA submitted start of October 2022 · First patient…

Reference is being made to the stock exchange release from 3 October 2022 where Arctic Bioscience gave a status update…

Reference is being made to the stock exchange release from 25 August 2022 regarding H1-2022 Reporting, where Arctic Bioscience announced…